Paper Review Records
All Paper Review Records
11 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
Real-world treatment patterns and survival outcomes in extensive-stage small cell lung cancer across first-line induction and maintenance therapy
Yi-Shao (Justus) Liu; Parth A Desai; Humera Khurshid; Anne C Chiang; Christine L Hann; Melissa L Johnson; Erik S Anderson; Rani Najdi; Jessie Wang; Xerxes PundoleShow moreShow less
1. Amgen Inc, Thousand Oaks, CA 91320, United States; 2. Department of Hematology & Medical Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, PA 19140, United States; 3. Brown University School of Medicine-Rhode Island Hospital, Providence, RI 02903, United States; 4. Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, United States; 5. Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, United States; 6. Sarah Cannon Research Institute, Nashville, TN 37203, United StatesShow moreShow less
Durable response to vebreltinib in heavily pretreated MET-amplified intrahepatic cholangiocarcinoma: a case report
Yingying Hang; Lu Bai; Hsiquan Hsu; Ying Chen; Fufeng Wang; Wuyan Xu; Xia Zhen; Zihao Wang; Yuan Li; Jun QianShow moreShow less
1. Department of Oncology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Provincial Hospital of Chinese Medicine, Nanjing 210029, China; 2. The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing 210023, China; 3. Jiangsu Collaborative Innovation Center of TCM Cancer Prevention and Treatment, Nanjing 210023, China; 4. Geneseeq Research Institute, Nanjing Geneseeq Technology Inc, Nanjing 210032, China; 5. Department of Pathology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, ChinaShow moreShow less
Immune checkpoint inhibitors induced autoimmune hemolytic anemia in patients with malignant cancer
Aoxi Liang; Yuanqiang Wu; Shengchi Chen; Jisheng Li; Yue Pan; Yixing Luo; Yue Zeng; Shijiao Yao; Shuxing Wang; Chunhong Hu; Xianling Liu; Fang WuShow moreShow less
1. Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha 410011, China; 2. Department of Oncology, Nanping First Hospital Affiliated to Fujian Medical University, Nanping 353000, China; 3. Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan 250012, China; 4. Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China; 5. Department of Oncology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China; 6. Xiangya School of Medicine, Central South University, Changsha 410013, China; 7. Hunan Cancer Mega-Data Intelligent Application and Engineering Research Centre, Changsha 410011, China; 8. Department of Oncology, Guilin Hospital of the Second Xiangya Hospital, Central South University, Guilin 541100, China; 9. Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital, Central South University, Changsha 410011, China; 10. Hunan Key Laboratory of Early Diagnosis and Precision Therapy in Lung Cancer, The Second Xiangya Hospital, Central South University, Changsha 410011, China; 11. FuRong Laboratory, Changsha 410078, China; 12. Changsha Thoracic Cancer Prevention and Treatment Technology Innovation Center, Changsha 410011, ChinaShow moreShow less
Treatment of metastatic solid pseudopapillary neoplasms
Courtney Porfido; Diane Reidy-Lagunes; Nitya RajShow moreShow less
1. Department of Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States; 2. Division of Medical Oncology, Duke Cancer Institute, Durham, NC 27710, United StatesShow moreShow less
Baseline 25-hydroxyvitamin D and progression-free survival in de novo metastatic hormone-sensitive prostate cancer: prognostic model development and external validation
Galip Can Uyar; Kadriye Başkurt; Orhun Akdoğan; Enes Yeşilbaş; Mustafa Ersoy; Tuba Uğur Tuzcu; Kadriye Bir Yücel; Mustafa Altınbaş; Ömür Berna Çakmak Öksüzoğlu; Gökşen İnanç İmamoğlu; Osman SütcüoğluShow moreShow less
1. Department of Medical Oncology, Etlik City Hospital, Ankara, 06170, Turkey; 2. Department of Medical Oncology, Faculty of Medicine, Gazi University, Ankara, 06500, Turkey; 3. Department of Medical Oncology, Kütahya City Hospital, Kütahya, 43100, TurkeyShow moreShow less
New prognosis indexes specific to Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma combining functional hepatic reserve and tumor burden
Koji Fujita; Rie Yano; Mai Nakahara; Kyoko Oura; Hironobu Suto; Asahiro Morishita; Takashi Himoto; Keiichi Okano; Hideki KobaraShow moreShow less
1. Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Takamatsu 760-8521, Japan; 2. Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa University, Takamatsu 760-8521, Japan; 3. Department of Medical Technology, Kagawa Prefectural University of Health Sciences, Takamatsu 761-0123, JapanShow moreShow less
FAQ
How long does ONCOLOGIST take to review a manuscript?
As of 2026-11-19, CrushSCI has 11 complete review records for ONCOLOGIST. The fastest paper went from submission to acceptance in 53 days (Symptom clusters and quality of life among patients with thyroid cancer during early survivorship: a national multicenter cross-sectional study, received 2026-06-05, accepted 2026-07-28); the slowest took 412 days. The average is 136.1 days and the median is 92 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
